← Back to Clinical Trials
Recruiting NCT07380763

NCT07380763 Comparison of Peri-intubation Oxygenation Values and Complications in Patients Intubated With the Delayed Versus Rapid Sequence Intubation Protocols

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07380763
Status Recruiting
Phase
Sponsor Kanuni Sultan Suleyman Training and Research Hospital
Condition Delayed Sequence Intubation
Study Type INTERVENTIONAL
Enrollment 140 participants
Start Date 2025-10-29
Primary Completion 2026-05-29

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Delayed Sequence IntubationRapid Sequence Intubation

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 140 participants in total. It began in 2025-10-29 with a primary completion date of 2026-05-29.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This study compares two different methods of helping patients breathe by placing a tube in their airway (intubation) in an emergency setting. These methods are called Rapid Sequence Intubation (RSI) and Delayed Sequence Intubation (DSI). The study focuses on adult patients who are still breathing on their own but need a breathing tube for medical reasons not related to an injury (non-trauma). The main goal of the research is to compare: * Oxygen levels before and after the procedure. * The patient's vital signs (such as heart rate and blood pressure). * The number of attempts needed to successfully place the tube and the time the procedure takes. * Blood gas results and any complications that occur during or shortly after the procedure. * Early survival (mortality) rates. While there are previous studies on trauma patients or small observational reports, there is currently no large-scale, multicenter randomized controlled trial that includes all non-trauma adult patients. What makes this study unique? Confirmation of Tube Placement: Researchers will use a specific measurement called end-tidal CO2 (etCO2) to confirm the tube is in the right place, a method not used in similar previous studies. Assessing Difficulty: This study will use the Cormack-Lehane classification system to measure how difficult the intubation was for each patient. Standardization: For the first time, breathing machine (ventilator) settings will be standardized for all patients in this type of study. Real-World Practice: By involving all emergency department physicians as practitioners, the study aims to show how these methods work across a wide range of medical teams.

Eligibility Criteria

Inclusion Criteria: 1. Aged 18 years or older 2. Presence of spontaneous breathing. 3. No prediction of a difficult airway prior to intubation. 4. Requirement for advanced airway management. 5. Not in cardiac arrest. 6. Decided to intubate due to non-traumatic etiologies. 7. Planned intubation using ketamine for sedation and rocuronium for paralysis. 8. Decision to intubate due to one of the following clinical conditions: 1. Acute Respiratory Failure: Patients with hypoxic or hypercapnic respiratory failure where adequate oxygenation cannot be achieved despite non-invasive ventilation. 2. Inability to Protect the Airway: Altered level of consciousness or increased risk of pulmonary aspiration due to conditions such as upper gastrointestinal bleeding, ileus, volvulus, gastric outlet obstruction, hypersalivation, or hyperemesis. 3. Shock States: Patients in any state of shock (hypovolemic, distributive, cardiogenic, obstructive) exhibiting severe altered mental status or declining respiratory status. 4. Neuroprotection: Need to terminate ongoing seizures resistant to medical therapy (status epilepticus), or situations requiring strict control of arterial carbon dioxide (PaCO₂) levels to manage increased intracranial pressure (ICP) in non-traumatic conditions (such as intracranial hemorrhage or severe encephalopathy). 9. Obtaining informed consent from the patient or their legally authorized representative. Exclusion Criteria: 1. Aged under 18 years. 2. Pregnancy. 3. Refusal to provide informed consent. 4. Cardiac arrest prior to intubation. 5. Anticipated difficult airway. 6. Intubation required due to traumatic etiologies. 7. Missing or incomplete patient data. 8. Patients assigned to the DSI protocol but for whom the decision to intubate was rescinded due to clinical improvement during the preoxygenation phase. 9. Use of a sedative agent other than ketamine for the RSI protocol. 10. Intubations performed by practitioners who have not received study-specific training on DSI and RSI protocols. 11. Duplicate enrollment due to recurrent presentations during the study period.

Contact & Investigator

Central Contact

Utku Murat Kalafat, Associate Professor

✉ utkumuratk@yahoo.com

📞 +90-507-262-74-04

Frequently Asked Questions

Who can join the NCT07380763 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Delayed Sequence Intubation. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07380763 currently recruiting?

Yes, NCT07380763 is actively recruiting participants. Contact the research team at utkumuratk@yahoo.com for enrollment information.

Where is the NCT07380763 trial being conducted?

This trial is being conducted at Istanbul, Turkey (Türkiye), Istanbul, Turkey (Türkiye), Istanbul, Turkey (Türkiye), Istanbul, Turkey (Türkiye).

Who is sponsoring the NCT07380763 clinical trial?

NCT07380763 is sponsored by Kanuni Sultan Suleyman Training and Research Hospital. The trial plans to enroll 140 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology